Literature DB >> 15728902

Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study.

E Frobert1, T Ooka, J C Cortay, B Lina, D Thouvenot, F Morfin.   

Abstract

Mutations in the thymidine kinase (TK) gene of herpes simplex virus (HSV) may confer resistance to acyclovir (ACV). Because of the high genetic polymorphism of this gene, discriminating between mutations related to resistance and mutations related to gene polymorphism can be difficult, especially when no sensitive strain has been previously isolated from the same patient. To assess the role of the mutations located at codons 51, 77, 83, and 175, previously detected in HSV-1 clinical isolates (F. Morfin, G. Souillet, K. Bilger, T. Ooka, M. Aymard, and D. Thouvenot, J. Infect. Dis. 182:290-293, 2000), in the acquisition of resistance to ACV, four mutants with site-directed mutations at these respective codons were constructed. The enzymatic activity of the proteins, produced using both a reticulocyte lysate system and a bacterial system, was evaluated using [(3)H]thymidine as substrate. This site-directed mutagenesis revealed that mutations at codons 51, 83, and 175 induce a loss of HSV-1 TK activity and are thus clearly involved in the acquisition of resistance to ACV. On the other hand, the mutation at codon 77 does not affect enzyme activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728902      PMCID: PMC549244          DOI: 10.1128/AAC.49.3.1055-1059.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance.

Authors:  S Chakrabarti; D Pillay; D Ratcliffe; P A Cane; K E Collingham; D W Milligan
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

2.  Acyclovir-resistant bilateral keratitis associated with mutations in the HSV-1 thymidine kinase gene.

Authors:  B Bodaghi; C Mougin; S Michelson; H Agut; P Dighiero; H Offret; E Frau
Journal:  Exp Eye Res       Date:  2000-10       Impact factor: 3.467

Review 3.  Herpesviral thymidine kinases: laxity and resistance by design.

Authors:  J S Evans; K P Lock; B A Levine; J N Champness; M R Sanderson; W C Summers; P J McLeish; A Buchan
Journal:  J Gen Virol       Date:  1998-09       Impact factor: 3.891

4.  Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues.

Authors:  J Bestman-Smith; I Schmit; B Papadopoulou; G Boivin
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed.

Authors:  I Schmit; G Boivin
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

6.  Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1.

Authors:  B A Larder; Y C Cheng; G Darby
Journal:  J Gen Virol       Date:  1983-03       Impact factor: 3.891

7.  Rapid phenotypic characterization method for herpes simplex virus and Varicella-Zoster virus thymidine kinases to screen for acyclovir-resistant viral infection.

Authors:  T Suzutani; M Saijo; M Nagamine; M Ogasawara; M Azuma
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

8.  Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients.

Authors:  F Morfin; G Souillet; K Bilger; T Ooka; M Aymard; D Thouvenot
Journal:  J Infect Dis       Date:  2000-06-19       Impact factor: 5.226

Review 9.  Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms.

Authors:  Christian Gilbert; Julie Bestman-Smith; Guy Boivin
Journal:  Drug Resist Updat       Date:  2002-04       Impact factor: 18.500

10.  Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up.

Authors:  C Danve-Szatanek; M Aymard; D Thouvenot; F Morfin; G Agius; I Bertin; S Billaudel; B Chanzy; M Coste-Burel; L Finkielsztejn; H Fleury; T Hadou; C Henquell; H Lafeuille; M E Lafon; A Le Faou; M C Legrand; L Maille; C Mengelle; P Morand; F Morinet; E Nicand; S Omar; B Picard; B Pozzetto; J Puel; D Raoult; C Scieux; M Segondy; J M Seigneurin; R Teyssou; C Zandotti
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

View more
  16 in total

1.  Development and evaluation of SYBR Green-I based quantitative PCR assays for herpes simplex virus type 1 whole transcriptome analysis.

Authors:  Cathryn E Garvey; Chris L McGowin; Timothy P Foster
Journal:  J Virol Methods       Date:  2014-03-04       Impact factor: 2.014

2.  Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.

Authors:  Sonia Burrel; Claire Deback; Henri Agut; David Boutolleau
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

3.  Antiviral activity of recombinant cyanovirin-N against HSV-1.

Authors:  Hong Yu; Zong-tao Liu; Rui Lv; Wen-qing Zhang
Journal:  Virol Sin       Date:  2010-12-21       Impact factor: 4.327

Review 4.  Antiviral drug resistance: mechanisms and clinical implications.

Authors:  Lynne Strasfeld; Sunwen Chou
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982

5.  Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma.

Authors:  Jubayer A Hossain; Md A Latif; Lars A R Ystaas; Sandra Ninzima; Kristoffer Riecken; Arnaud Muller; Francisco Azuaje; Justin V Joseph; Krishna M Talasila; Jiwan Ghimire; Boris Fehse; Rolf Bjerkvig; Hrvoje Miletic
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

Review 6.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

7.  Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses.

Authors:  N Coen; U Singh; V Vuyyuru; J J Van den Oord; J Balzarini; S Duraffour; R Snoeck; Y C Cheng; C K Chu; G Andrei
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

8.  Longitudinal Characterization of Herpes Simplex Virus (HSV) Isolates Acquired From Different Sites in an Immune-Compromised Child: A New HSV Thymidine Kinase Mutation Associated With Resistance.

Authors:  Andrew H Karaba; Laura K Cohen; Taly Glaubach; Sarah J Kopp; Jennifer L Reichek; Hawke H Yoon; Xiaotian T Zheng; William J Muller
Journal:  J Pediatric Infect Dis Soc       Date:  2012-05-03       Impact factor: 3.164

9.  An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection.

Authors:  Paul J Park; Thessicar E Antoine; Asim V Farooq; Tibor Valyi-Nagy; Deepak Shukla
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-27       Impact factor: 4.799

10.  Antiherpesvirus activities of two novel 4'-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases.

Authors:  Natacha Coen; Sophie Duraffour; Kazuhiro Haraguchi; Jan Balzarini; Joost J van den Oord; Robert Snoeck; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.